Vol. 5 No. 5 (2025)
Reimbursement Recommendations

Daratumumab (Darzalex SC)

decorative image of the issue cover

Published May 21, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Darzalex SC in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) followed by maintenance treatment in combination with lenalidomide be reimbursed by public drug plans for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant (ASCT), if certain conditions are met.
  • Darzalex SC should only be covered to treat patients aged 18 years or older with NDMM who are eligible to receive ASCT and have a good performance status. Patients must not have received prior systemic therapy (other than corticosteroids) for multiple myeloma (MM), and there must not be signs that the cancer has spread to the protective layers of the brain and spinal cord (known as the meninges).
  • Darzalex SC should only be reimbursed if prescribed in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, by clinicians with expertise in the diagnosis and management of MM, and if the cost of Darzalex SC is reduced.